SNORA29: A Non-Coding RNA Molecule with A Variety of Functions in Eukaryotic Cells

Target Name: SNORA29

NCBI ID: G677812

SNORA29

Other Name(s): Small nucleolar RNA, H/ACA box 29 | small nucleolar RNA, H/ACA box 29 | ACA29

SNORA29: A Non-Coding RNA Molecule with A Variety of Functions in Eukaryotic Cells

SNORA29, also known as Small Nucleolar RNA (snRNA), is a non-coding RNA molecule that is primarily located in the nucleolus of eukaryotic cells. It plays a crucial role in the regulation of gene expression, DNA replication, and other cellular processes. SNORA29 has been identified as a potential drug target and biomarker due to its unique structure and function.

SNORA29 is a small molecule that is approximately 200 nucleotides in length. It is composed of a stem-loop structure, which consists of a series of alternating 5' and 3' ends. The stem-loop region is the most conserved part of the molecule, and it is involved in the formation of a stable hairpin-like structure. This structure is important for the stability and function of the molecule.

SNORA29 has been shown to have a variety of functions in different cellular contexts. One of its most well-studied functions is its role in regulating gene expression. SNORA29 has been shown to interact with various protein factors, including the RNA polymerase II complex. This interaction allows SNORA29 to regulate the activity of RNA polymerase II and ultimately control gene expression.

Another function of SNORA29 is its role in DNA replication. SNORA29 has been shown to play a role in the regulation of DNA replication by the enzyme responsible for this process, called DNA polymerase. Specifically, SNORA29 has been shown to interact with the protein responsible for the initiation of DNA replication, called DnaB. This interaction allows SNORA29 to regulate the activity of DNA polymerase and ensure accurate replication of the genetic material.

SNORA29 has also been shown to play a role in the regulation of cellular processes such as cell growth, apoptosis, and inflammation. For example, studies have shown that SNORA29 is involved in the regulation of cell growth and that it can induce cell death under certain conditions. Additionally, SNORA29 has been shown to be involved in the regulation of inflammation, and it has been shown to play a role in the development of certain diseases.

Due to its unique structure and function, SNORA29 has been identified as a potential drug target and biomarker. Researchers have been studying the potential mechanisms of action of SNORA29 and have identified several potential targets for drug development. For example, one potential target for SNORA29 is the use of small molecule inhibitors to reduce the activity of SNORA29 and inhibit its function in gene expression and DNA replication.

Another potential target for SNORA29 is the use of small molecule inhibitors to inhibit the activity of DNA polymerase and ensure accurate replication of the genetic material. This could be useful for the treatment of certain diseases that are caused by errors in DNA replication, such as cancer.

In conclusion, SNORA29 is a small molecule that plays a crucial role in the regulation of gene expression, DNA replication, and other cellular processes. Its unique structure and function make it an attractive target for drug development and research. Further studies are needed to fully understand the mechanisms of action of SNORA29 and to identify potential targets for drug development.

Protein Name: Small Nucleolar RNA, H/ACA Box 29

The "SNORA29 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORA29 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets